Background: HESA-A is a natural biological compound of herbal—marine origin. The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer. Methods: Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied. Patients received HESA-A 50 mg/kg/d orally in 2 to 3 divided doses for 6 months. The patients were assessed at the start and end of the 1st, 2nd, 4th, 8th, 12th, 16th, 20th, and 26th weeks of the study. The Karnofsky Performance Scale questionnaire was completed for each patient. Results: The mean Karnofsky performance score increased from 33.6 ± 9.8 to 63.3 ± 11 after 10 weeks of study. No significant hepatic or hematological adverse effects were seen during the study. Conclusion: It seems that HESA-A is an effective and safe anticancer drug, which can be used in selected patients.
Bullard KM, Rothenberger DAColon, rectum and anus. In: Brunicardi FC , Andersen DK, Billiar TR, Hunter JG, eds. Schwartz's Principle of Surgery. 8th ed. New York, NY: McGraw-Hill; 2005:1497-1505.
2.
Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in2006. Ann Oncol. 2007;18: 581-592.
3.
Ansari R., Mahdavinia M., Sadjadi A., et al. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett . 2006;240:143-147.
4.
Collier DA, Neidle S.Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthroquinones. J Med Chem. 1988;31:847-857.
5.
Costello AJA randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology . 2001;57:182-184.
6.
Burk RFSelenium, an antioxidant nutrient. Nutr Clin Care. 2002;5:75-77.
7.
Wang GQ, Dawsey SM, Li JY, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of esophagus and stomach: results from the general population trial in Linxian, China. Cancer Epidemol Biomarkers Prev. 1994;3:161-166.
8.
Melendez E.Titanium complex in cancer treatment. Crit Rev Oncol Hematol . 2002;142:309-315.
9.
Fernandez-Banares F., Cabre E., Esteve M., et al. Serum selenium and risk of large colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol. 2002;97: 2103-2108.
10.
Denkhaus SE , Salinkow K.Nickel essentiality, toxicity and carcinogenicity . Crit Rev Oncol Hematol. 2002;42:35-56.
11.
Ji YJ, Xiao B., Wang ZH, Cui MZ, Lu YYThe suppression effect of light-rate earth elements on proliferation of two cancer cell lines. Biomed Environ Sci. 2000 ;13:287-292.
12.
Evangelov AMVanadium in cancer treatment. Crit Rev Oncol Hematol. 2002;42:249-256.
13.
Hiraoka K., Komiya S., Hamada T., Zenmyo M., Inove A.Osteosarcoma cell apoptosis induced by selenium. J Orthop Res. 2001;19: 809-814.
14.
Ahmadi A., inventor. Method of preparation of an antitumor herbal drug [HESA-A] . Islamic Republic of Iran patent27741. 2002.
15.
Ahmadi A., Naderi G., Asgary S.Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005;31:1-6.
16.
Ahmadi A., Sadeghi Aliabadi H.Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru. 2003;11:82-87.
17.
Zeng H., Combs GF Jr.Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008;19:1-7.
18.
Caruso F., Rossi M.Antitumor titanium compounds. Mini Rev Med Chem. 2004;4:49-60.
19.
Guo J., Deng W., Zhang L., Li C., Wu P., Mao P.Prediction of prostate cancer using hair trace element concentration and support vector machine method. Biol Trace Elem Res. 2007; 116:257-272.
20.
Hajhashemi V., Ghafghazi T., Balali M., et al. Toxicological studies on an anticancer drug (HESA-A) with marine origin. Med J Islam Acad Sci. 2001;14:145-149.
21.
Ahmadi A., Mohgheghi MA, Sharif-Tabrizi A.Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. Paper presented at: Proceedings of the First National Congress on Cancer Research; April 5-8, 2001 ; Orumiah, Iran.
22.
Sadeghi-Aliabadi H., Ahmadi A.Cytotoxicity and antitumor properties of a marine compound on cancer cell (HESA-A). Med J Islam Acad Sci. 2000;13:55-61.
23.
Fazly Bazzaz BSHESA-A, its cytotoxicity and mutagenicity . J Oncol Pharm Pract. 2006;12:60.
24.
Ahmadi A.Analysis of HESA: Report of Atomic Energy Organization of Iran (AEOI). Tehran, Islamic Republic of Iran: Research Division, AEOI; 2004.
